Pharma Marketletter articles from January 2005

Pharma Marketletter archives from January 2005

Priority review for Chiron's Pulminiq.(Brief Article)
January 3, 2005... Chiron Corp of the USA says that the US Food and Drug Administration has accepted for review its New Drug Application for Pulminiq (cyclosporine) inhalation solution. Furthermore, the filing has been granted priority review designation, noted...

FDA fast-track for J&J/S-P's Remicade.(Food and Drug Administration)(Brief Article)
January 3, 2005... The US Food and Drug Administration has awarded fast-track designation to Schering-Plough/Johnson & Johnson's Remicade (infliximab) for the treatment of active ulcerative colitis. The agent is currently undergoing two multicenter,...

New use for Schering-Plough's Nasonex.(Brief Article)
January 3, 2005... Schering-Plough's Nasonex (mometasone furoate monohydrate) Nasal Spray 50mcg has been cleared by the US Food and Drug Administration for the treatment of nasal polyps in patients 18 years of age and older. The decision was based on findings...

Roche's Pegasys on track for new use in EU.
January 3, 2005... Swiss drug major Roche says that the European Medicines Agency has granted a positive opinion for the use of Pegasys (peginterferon alfa-2a), in combination with Copegus (ribavirin), for the treatment of hepatitis C in patients co-infected with...

GPC Biotech signs deal with Debiopharm.(Brief Article)
January 3, 2005... Germany-headquartered GPC Biotech and Switzerland's Debiopharm SA have signed a licensing agreement for the former's preclinical small-molecule MHC class II antagonist program. Under the terms of the deal, Debiopharm has acquired exclusive...

Medicis licenses technology to Ansata.(Brief Article)
January 3, 2005... US firms Medicis and Ansata Therapeutics have signed an exclusive development and license deal, as well as entering into other ancillary agreements. Under the terms of the development and license accord, Medicis will obtain the exclusive,...

Acrux grants CSL Fentanyl rights.(Brief Article)
January 3, 2005... Australian pharmaceutical firm Acrux has expanded its relationship with CSL by granting the firm distribution rights to its pain-relief product, Fentanyl MDTS (metered dose transdermal system), currently in Phase I clinical evaluation. ...

NGB launches malaria treatment Artem.(Nigeria-German Chemical)(Brief Article)
January 3, 2005... Nigeria-German Chemical, a leading Nigerian pharmaceutical firm, in conjunction with Chinese drugmaker Kunming Pharmaceutical, has launched Artem, a new anti-malaria drug to combat the disease in the country. Paul Okonkwo, of the...

BPI tells Germany not to fear drug price rises.(Brief Article)
January 3, 2005... Germany's Federal Association of the Pharmaceutical Industry, the BPI, has warned that current media reports forecasting substantial rises in drug prices are causing unnecessary concern to patients and those insured under the state health...

Oxford Bio's SMN1-G effective for SMA.(spinal muscular atrophy)(Brief Article)
January 3, 2005... UK gene therapy group Oxford BioMedica has published promising preclinical results for its SMN1-G in the Journal of Clinical Investigation, which suggest that the drug may have potential as a treatment for spinal muscular atrophy. In...

Aspen given green light to supply generic AIDS drugs.(Brief Article)
January 3, 2005... South African drug firm Aspen Pharmacare has received the go-ahead from the US Food and Drug Administration to produce and supply generic anti-AIDS drugs, under US President George W Bush's Emergency Plan for AIDS Relief - a five-year,...

Serologicals prices public offering.(Brief Article)
January 3, 2005... Serologicals Corp of the USA has priced the public offering of 5,562,860 shares of its common stock, comprising 4,200,000 primary shares and 1,362,860 secondary shares, to the public at $22.80 each. Gross proceeds of the combined primary...

Xtrana and Alpha Innotech to merge.(Brief Article)
January 3, 2005... USA-based firms Xtrana and Alpha Innotech have entered into a definitive agreement under which the latter will combine with a wholly-owned subsidiary of the former in a reverse merger transaction. Under the terms of the deal, security...

Abbott issues 2005 outlook and confirms 2004 guidance.(Brief Article)
January 3, 2005... US drug major Abbott Laboratories has forecast 2005 earnings per share of $2.47-$2.53, excluding one-time charges, and $2.45-$2.51 a share including charges, based on 10%-12% growth in sales. The group also reaffirmed guidance for full-year...

Czech Health Minister attacked for policy, which favors her son's employer Zentiva.(Czech Republic)(Zentiva Group)
January 3, 2005... In what was described as a move to save the Czech Republic's health insurance system up to 200 million koruna ($8.7 million) a year without raising patients' costs, the country's Health Ministry entered a deal with domestic generic drugmaker...

European and French generics market set to double by 2008, says Ratiopharm.
January 3, 2005... Low-cost generic drugs have a very good future ahead of them, both in Europe and in France, according to Hubert Olivier, president of the French subsidiary of the leading German generics group Ratiopharm. Mr Olivier said that the pace and...

German campaign sees surge in drug spending.(Brief Article)
January 3, 2005... German health funds, the federation of panel doctors, the pharmacy federation and the Ministry of Health are together so concerned about the prospects of a sharp rise in drug spending in 2005 that they have united to set out principles that...

South Korea poised to become a major pharma industry player?
January 3, 2005... Despite the ongoing risks and costs of drug development, as well as a continuation of a general "low ebb" in the industry, new players are using partnering tactics to build a presence in the global pharmaceutical market, most notably South...

Brazil threatens to breach AIDS patents.(Brief Article)
January 3, 2005... The Brazilian government is threatening to break several patents of international pharmaceutical companies in order to produce cheaper anti-AIDS drugs locally, reports the European AIDS Treatment Group. The move is part of Brazil's...

Saving from TESCM for European life sciences companies.(Tax Effective Supply Chain Management)
January 3, 2005... Companies in the European life sciences industry can potentially save significant amounts of money, up to 5% of turnover in specific cases, according to the latest report from consultants Capgemini. The potential saving on average would be more...

Avanir sees fiscal 2004 net loss widen.(Brief Article)
January 3, 2005... San Diego, USA-based Avanir Pharmaceuticals, which focuses on treatments for chronic diseases, has posted a net loss of $28.2 million, or $0.36 per share, for its fiscal full year to September 30, 2004, climbing 21% from the prior year's...

CATs shareholders OK AstraZeneca subscription.(Brief Article)
January 3, 2005... The UK's Cambridge Antibody Technology, a company engaged in drug discovery through the use of human monoclonal antibodies, says that all resolutions were agreed at is extraordinary general meeting, held on December 16. Application has...

AstraZeneca's Iressa shows no overall survival advantage.(Brief Article)
January 3, 2005... AstraZeneca has announced that the initial analysis of the primary endpoint of Study 709, Iressa (gefitinib) Survival Evaluation in Lung cancer (ISEL) with 1,692 patients has been conducted, and shows that the drug failed to significantly...

Pfizer setback with Celebrek trial.(Brief Article)
January 3, 2005... Pfizer said it received new information about the cardiovascular safety of its COX-2 inhibitor Celebrex (celecoxib) based on an analysis of two long-term cancer trials. As reported to Pfizer by the Data Safety and Monitoring Board, one of...

Americans have high trust in generics; survey.(Brief Article)
January 3, 2005... The vast majority of Americans trust that generic medications are as safe and effective as their brand-name counterparts, according to a new national survey sponsored by Rx Outreach. This year marks a milestone for generic prescription...

Abbott's Humira filed for new use in USA and EU.(Abbott Laboratories)(European Union)(Brief Article)
January 3, 2005... US drug major Abbott Laboratories says it has simultaneously filed a supplemental Biologics License Application with the US Food and Drug Administration and a Marketing Authorization Application with the European Medicines Agency for the use of...

French biotechnology sector investment is waning, says France Biotech.
January 3, 2005... Last year, the biotechnology sector was characterized by the "timid return to green" of some US indicators, but this slow recovery across the Atlantic failed to benefit European biotechnology enterprises which, in the period to June 30, 2004,...

Sanofi-Aventis to shed jobs in Germany?(Brief Article)
January 3, 2005... Sanofi-Aventis' chief executive, Jean-Francois Dehecq, has started talking tough to the German authorities over its drug sector policy. He has threatened that the company will move out of Germany unless there is a change in the drug pricing...

Lilly adds liver warning to Strattera label.(Eli Lilly and Co.)
January 3, 2005... The USA's Eli Lilly has added a safety warning, in bold, to the label of Strattera (atomoxetine HCl), the first non-stimulant treatment for attention-deficit hyperactivity disorder, which states that the drug should be discontinued immediately...

deCODE to conduct Ph II trial in asthma.(phase two clinical trial for asthma drug)(Brief Article)
January 3, 2005... Reykjavik, Iceland-headquartered deCODE genetics says it has entered into an agreement with an undisclosed company under which it will run a Phase II information-rich clinical study of a third-party compound as part of a drug development...

Eyetech due $90M as FDA clears Macugen.(Eyetech Pharmaceuticals)(Food and Drug Administration)(Brief Article)
January 3, 2005... Eyetech Pharmaceuticals and Pfizer's Macugen (pegaptanib sodium injection), the first in a new class of ophthalmic drugs to specifically target vascular endothelial growth factor, has been approved by the US Food and Drug Administration for the...

CHMP issues positive opinion on palonosetron.(Committee for Medicinal Products for Human approves marketing for product from Helsinn Healthcare)(Brief Article)
January 3, 2005... Swiss privately-owned pharmaceutical group Helsinn Healthcare says that, following the European Union's Centralized Procedure and on the basis of quality, safety and efficacy data, the Committee for Medicinal Products for Human Use (CHMP) has...

Mymetics 's HIV vacc in late preclinical trials.(Mymetics Corp., HIV vaccine)(Brief Article)
January 3, 2005... Mymetics Corp of the USA has been given the green light to commence advanced preclinical testing of its trimeric gp41 vaccine for HIV in nonhuman primates by the US National Institute of Allergy and Infectious Diseases division of the National...

Terumo initiates Nobori clinical study.(Brief Article)
January 3, 2005... Terumo Europe NV, the Belgian affiliate of Japan's Terumo Corp, says it has initiated the first clinical trial for its Nobori biolimus A9-eluting coronary stent. The Phase I clinical trial is designed to compare the group's stent system...

Hana provides update on clinical status of IPdR.(Hana Biosciences)(Brief Article)
January 3, 2005... The USA's Hana Biosciences, which is focused on the development of treatments for unmet medical needs in the areas of cancer and immunological diseases, has provided an update on the clinical development program of its radiosensitization...

Australia's TGA must tighten controls on non-Rx drugs, says Audit Office.
January 3, 2005... More rigor around the systems, procedures and resource management is required within the Australian Therapeutic Goods Administration's framework for regulating non-prescription medicines, in order to provide assurance that these are...

B-MS and Gilead set up JV to market triple AIDS drugs.(Bristol-Myers Squibb, Gilead Sciences joint venture)(Brief Article)
January 3, 2005... US firms Bristol-Myers Squibb and Gilead Sciences have announced details of a joint venture to develop and commercialize the fixed-dose combination of the former's Sustiva (efavirenz) and the latter's Truvada (emtricitabine and tenofovir...

IVAX announces $283M placement.(Brief Article)
January 3, 2005... USA-based IVAX Corp has announced the sale of $283 million of its 17/8% senior convertible notes due 2024 to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. The company has also granted the...

Altracel buys oral care business for 8M euros.(Brief Article)
January 3, 2005... Ireland's Alltracel Pharmaceuticals, a brand-focused, biopharmaceutical R&D company specializing in the medical device and food ingredient markets, says it has conditionally agreed to acquire the entire issued share capital of Westone Products,...

Guilford completes sale and leaseback for $19.4M in net proceeds.(Brief Article)
January 3, 2005... Guilford Pharmaceuticals of the USA says that it has completed a sale and leaseback of its facilities in Baltimore, Maryland, with BioMed Realty Trust, a real estate investment trust focused on acquiring, owning, leasing and developing...

Inion in European distribution deal for craniomaxillofacial prods.(Brief Article)
January 3, 2005... Inion, a Finland-based company focused on the development of novel biodegradable medical implants, and Stryker Corp, one of the leaders in the worldwide orthopedic market, have entered into an exclusive agreement for the European distribution...

$12.5M placing by Aradigm.(Brief Article)
January 3, 2005... US firm Aradigm Corp says that it has entered into a definitive agreement for a $12.5 million private placement of common stock and the concurrent issue of warrants for the purchase of common stock. Under the terms of the financing, Aradigm...

MorphoSys extends deal with Schering AG.(Brief Article)
January 3, 2005... MorphoSys has announced the extension of its collaboration with fellow German firm Schering AG, to develop innovative antibody therapeutics and in vivo diagnostics. The alliance, originally signed in December 2001, is extended by at least two...

CAT prevails in Humira royalty dispute with Abbott.(Brief Article)
January 3, 2005... A UK High Court judge, Justice Laddie, has ruled in favor of England-based Cambridge Antibody Technology in its dispute with US health care major Abbott Laboratories over royalties on Humira (adalimumab), for which the latter has marketing...

Few US employers to drop coverage in 2006, after Medicare drug benefit starts.
January 3, 2005... This year, 8% of US employers have eliminated subsidized health benefits for future retirees, while only 1% say they are likely to terminate subsidized coverage for current retirees next year, although 11% are likely to terminate coverage for...

Radon gas increases risk of lung cancer.(Brief Article)
January 3, 2005... Radon, a naturally-occurring, colorless, odorless, radioactive gas found at varying levels in all houses in the UK and across Europe, is responsible for a significant number of lung cancer deaths, particularly among smokers, according to...

IsoTis sells wound-management unit to DFB.(Brief Article)
January 3, 2005... IsoTis OrthoBiologics has sold its wound-management activities to fellow US firm DFB Pharmaceuticals for an undisclosed amount. DFB, through its subsidiary Healthpoint, is a USA-based market leader in advanced wound-care, dermatology, and...

Inyx to buy Aventis' Puerto Rico unit.
January 3, 2005... Inyx, a specialty US pharmaceutical firm with a focus on niche drug-delivery technologies and products, says that it has signed a definitive agreement with Aventis Pharmaceuticals, a part of the French Sanofi-Aventis group, to acquire certain...

German drug co's to get 2005 sales boost?(Brief Article)
January 3, 2005... The German pharmaceutical industry is widely expected to increase sales sharply in 2005 owing to the late introduction of a key government health reform and the reduction of the obligatory health fund discount. Drugmakers are expecting extra...

AstraZeneca shares slump as promotion of Iressa is suspended.
January 3, 2005... Anglo-Swedish pharmaceutical major AstraZeneca saw its share price slump on December 17, after the company announced that clinical trials with its lung cancer drug Iressa (gefitinib) failed to met their primary endpoint, prolonging overall...

Flamel Tech initiates Medusa Phase I/II trial.(Brief Article)
January 3, 2005... French biopharmaceutical group Flamel Technologies SA, which is primarily focused on the development of two unique polymer-based delivery technologies for medical applications, Micropump and Medusa, has reported the first patient enrollment in...

Advancis to launch Ph III trial of pediatric amoxcicillin.(Brief Article)
January 3, 2005... Advancis Pharmaceutical says it has completed a pre-Phase III meeting with the US Food and Drug Administration regarding its pediatric product development program for Amoxicillin PULSYS. The group believes its trial design and regulatory...

IntegraGen secures DNA chips supply deal.(Brief Article)
January 3, 2005... Paris, France-headquartered IntegraGen says it has entered into a contract to develop, manufacture and supply novel DNA chips to La Ligue Nationale Contre le Cancer. The chips are a type of microarray based on the firm's proprietary...

GeoPharma's Mucotrol to hit shelves in 2nd-half 2005.(Brief Article)
January 3, 2005... The USA's GeoPharma has unveiled its strategy for the launch of the oral gel wafer Mucotrol for the treatment of mouth sores and lesions, news which pushed its shares up 6.5% to close at $5.27 on December 17, the day of the announcement. ...

Alcon files Retaane in Europe and USA.(Brief Article)
January 3, 2005... Texas, USA-based world leader in eye care Alcon says it has filed a Marketing Authorisation Application with the European Medicines Agency and a New Drug Application with the US Food and Drug Administration for Retaane (anecortave acetate for...

Roche's Invirase 500mg gets US approval.(Brief Article)
January 3, 2005... Swiss drugmaker Roche has obtained US Food and Drug Administration approval of a new 500mg film-coated tablet formulation of its HIV protease inhibitor Invirase (saquinavir mesylate), designed for use in combination with a small dose of...

Avastin cleared for cancer in Switzerland.(Roche Holding Ltd.)(Brief Article)
January 3, 2005... Swiss drug major Roche says that its angiogenesis inhibitor Avastin (bevacizumab) has been cleared by the Swiss health authority, Swissmedic, for the treatment of patients with previously untreated metastatic cancer of the colon or rectum,...

Cardiome's drug effective in AF.(Brief Article)
January 3, 2005... Shares in Canadian drugmaker Cardiome shot up 21% to C$9.10 on the Toronto Stock Exchange on December 20, following positive results of a Phase III clinical trial of RSD1235, in development with partner Fujisawa Healthcare for the treatment of...

Cilansetron review extended by FDA.(Brief Article)
January 3, 2005... The US Food and Drug Administration has extended its review of Solvay Pharmaceuticals' New Drug Application for cilansetron to April 1, 2005, from January 1. Solvay is seeking approval to market its investigational 5-HT3 receptor antagonist for...

Solvay makes bid for Sweden's Neopharma.(Brief Article)
January 3, 2005... Belgian drugmaker Solvay has launched a friendly takeover bid for the Swedish drug enterprise Neopharma. Solvay has said that 70% of Neopharma's shareholders have already agreed to sell their stakes in the firm. No price has been disclosed and...

USPTO approves Sanofi-Aventis Lovenox patent renewal.(Brief Article)
January 3, 2005... Sanofi-Aventis has received approval from the US Patents and Trademark Office for its request for a renewal of the patent on its major anti-thrombosis drug Lovenox (enoxaparin). The company said the new patent from the USPTO would probably...

Valeant to sell one Mexican facility.(Brief Article)
January 3, 2005... California, USA-based Valeant Pharmaceuticals says that it has agreed to sell one of its manufacturing facilities in Mexico City, Mexico, to Inmobiliaria Zerboni. Terms of the transaction were not disclosed. Valeant's chief executive,...

Schering-Plough completes expansion of Shiga plant in Japan.(Brief Article)
January 3, 2005... Schering-Plough says that its Japanese subsidiary has completed a project to expand its production plant in Shiga, Japan, which supplies the group's drugs to that market. The company has also completed renovation of existing manufacturing...

EMEA Management Board finalizes long-term plan, adopts 2005 program/budget.(European Medicines Agency)
January 3, 2005... The Management Board of the European Medicines Agency has now endorsed the Road Map, or long-term plan for the EMEA (Marketletter June 28) that sets out the direction for the Agency to 2010, including implementation of the new pharmaceutical...

ABPI consults on Code of Practice review.(Association of the British Pharmaceutical Industry )(Brief Article)
January 3, 2005... The Association of the British Pharmaceutical Industry has announced that an independent market research company will be approaching a number of organizations on behalf of the ABPI to ascertain their views on the Association's Code of Practice...

Give patients more access to drug info, say Irish GPs.(general practitioners)
January 3, 2005... 96% of Irish general practitioners believe that their patients are more informed about health issues than they were five years ago, but more than half think patients should have even more access to information about their medicines and nine out...

Enhance and Ardent close merger.(Brief Article)
January 3, 2005... US companies Enhance Biotech and Ardent Pharmaceuticals say that their previously-announced merger has been consummated (Marketletter November 8). As a consequence of the transaction, Ardent is now a wholly-owned subsidiary of Enhance. The...

UK Ministry advice on COX-2s.(United Kingdom)(Brief Article)
January 3, 2005... The UK's Medicines and Healthcare products Regulatory Agency has issued new advice on COX-2 inhibitor anti-inflammatory drugs, including Pfizer's blockbuster Celebrex (celecoxib), after data from a study conducted by the US Cancer Institute...

European market for bone morphogenic proteins in spine fusion.(Frost and Sullivan Inc.)
January 3, 2005... High growth is forecast for novel technologies used either as adjuncts or as alternatives to current surgical procedures for the fusion of spinal vertebrae. Bone morphogenic proteins, a new and innovative class of natural growth factors,...

Bayer and Stada hit by FDA warning on naproxen.(Food and Drug Administration)(Brief Article)
January 3, 2005... Two German pharmaceutical companies, Bayer and Stada Arzneimittel, saw their share prices hit on December 20, after the US Food and Drug Administration issued a warning on the generic analgesic/anti-inflammatory drug naproxen. The FDA...

Pfizer's Celebrex also found to have CD risks; company halts drug's DTC ads.(cardiovascular risk)
January 3, 2005... As a result of new data showing that its best selling COX-2 inhibitor Celebrex (celecoxib), in high doses, demonstrated an increased risk of cardiovascular events to placebo, Pfizer has, at the request of the US Food and Drug Administration...

S African Appeal Court rejects Rx price regs.(South Africa)(Brief Article)
January 3, 2005... The South African government's controversial new drug pricing regulations (Marketletters passim) have been scrapped by the Bloemfontein Court of Appeal, the country's highest appellant authority, on the grounds that they were not viable for the...

S-P to pay $6M+ to Pa Medicaid program in Claritin pricing case.
January 3, 2005... Jerry Pappert, Attorney General of the US state of Pennsylvania, has said that his Medicaid Fraud Control Section has secured $6.1 million for the state Medicaid program as its share of a national settlement with Schering-Plough (Marketletter...

US Veterans care "better than that for population:" study.
January 3, 2005... Patients enrolled in the US Department of Veterans Affairs health system are significantly more likely than similar people in the general population to receive preventive and chronic care recommended by well-established national standards,...

Positive Ph I/II data for HuMax-Inflam/MDX-018.(Brief Article)
January 3, 2005... Denmark's Genmab A/S and US firm Medarex have reported encouraging safety and efficacy data from a Phase I/II trial evaluating HuMax-Inflam/MDX-018, a fully-human antibody developed using the latter group's UltiMAb technology, in the treatment...

Myzozyme MAA lifts Genzyme.(Marketing Authorization Application )(Brief Article)
January 3, 2005... The USA's Genzyme has received notification from the European Medicines Agency that its Marketing Authorization Application for Myozyme, a recombinant human acid alpha-glucosidase enzyme-replacement therapy for Pompe disease, has been accepted....

Pharmexa's AutVac to enter Ph II in Poland.(Brief Article)
January 3, 2005... Denmark's Pharmexa says it has been granted approval for its planned Phase II trial with the HER-2 Protein AutoVac breast cancer vaccine in Poland. The trial is designed to investigate the clinical benefit of the vaccine, including tumor...

Further doubt cast over safety of Bextra.(Brief Article)
January 3, 2005... Adding to the current safety concerns surrounding the class of COX-2 inhibitors, following the sudden and voluntary withdrawal of Merck & Co's Vioxx (rofecoxib; Marketletters passim), researchers at the Vanderbilt University School of Medicine...

454 Life Sciences assists new drug for TB study.(Brief Article)
January 3, 2005... The USA's 454 Life Sciences, a majority-owned subsidiary of CuraGen, says that its proprietary whole genome sequencing technology was used by researchers at Johnson & Johnson Pharmaceutical R&D to help understand the foundations of tuberculosis...

NIH: No higher CV risk seen in ADAPT study with Celebrex.(National Institutes of Health)(cardiovascular risk)(Brief Article)
January 3, 2005... The US National Institutes of Health has reported that no increased cardiovascular risk was seen in 2,400 elderly patients taking Pfizer's COX-2 inhibitor Celebrex (celecoxib; 400mg daily) for up to three years as part of the Alzheimer's...

GW's cannabis drug gets Qualifying Notice.(Brief Article)
January 3, 2005... UK-based GW Pharmaceuticals' Sativex, a cannabis-based medicinal extract product, is one step closer to approval following the receipt of a Qualifying Notice from the Canadian health authority, Health Canada, which effectively allows group to...

Nabi files MAA for StaphVAX.(Nabi Biopharmaceuticals)(Marketing Authorization Application)(Staphylococcus aureus polysaccharide conjugate vaccine)(Brief Article)
January 3, 2005... The USA's Nabi Biopharmaceuticals has submitted a Marketing Authorization Application to the European Medicines Agency seeking approval for StaphVAX (Staphylococcus aureus polysaccharide conjugate vaccine) for the prevention of S aureus...

Pharmagene's shares slump as it drops CF program.(Brief Article)
January 3, 2005... UK-based drug delivery group Pharmagene had lost a quarter of its capital value by mid-morning trading on December 22, its shares plunging 25% to 31 pence as results of an initial Phase IIa proof-of-concept study of PGN0052 showed no...

US Surgeon-General warns over Canadian prescription drug imports.
January 3, 2005... Any legislation to permit the importation of foreign prescription drugs into the USA should only be done in a way that provides the statutory authority and substantial resources needed to effectively regulate such imports and, most importantly,...